A landmark study published last year by CU Anschutz researchers highlighted the seriousness of T2D in youth
Notably, GLP-1RAs demonstrated superior improvements in FMD compared to sulfonylureas and lifestyle interventions in multiple randomized controlled trials, including in patients with T2DM without overt CVD
First New Drug Successful The first representative of this new class of drugs has already been approved in the U.S.A
Regular monitoring of weight, body measurements, and symptoms is essential, with professional support from registered dietitians for optimal outcomes and safety
Results were reported as odds ratios (ORs) with their 95% confidence interval (95% CI)
Closest Analog: Cagrilintide + Semaglutide REDEFINE 1 (Garvey et al., NEJM 2025) is the only Phase 3 trial of an amylin + incretin co-administered combination in adults without diabetes